The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Clinical and Translational Medicine

Table 4 EDSS scores in the control group in each time intervals

Time intervals	Paired difference			T	df	Significance
Time intervals	Mean	Standard deviation	95% confidence interval	T	df	Significance
1–12	− 0.58	0.70	− 0.84, − 0.32	− 4.59	29	0.001
2–12	− 0.58	0.70	− 0.84, − 0.32	− 4.59	29	0.001
3–12	− 0.55	0.71	− 0.82, − 0.28	− 4.24	29	0.001
4–12	− 0.47	0.66	− 0.71, − 0.22	− 0.39	29	0.001
5–12	− 0.27	0.57	− 0.48, − .0.05	− 2.57	29	0.016
6–12	− 0.25	0.54	− 0.45, − 0.05	− 2.55	29	0.016
7–12	− 0.23	0.43	− 0.39, − 0.07	− 0.97	29	0.006
8–12	− 0.13	0.41	− 0.29, 0.02	− 1.77	29	0.088
9–12	− 0.03	0.35	− 0.10, 0.16	0.53	29	0.601
10–12	0.05	0.5	− 0.01, 0.11	0.80	29	0.083
11–12	0.02	0.09	− 0.02, 0.05	1.00	29	0.326